Korro Bio, Inc. (KRRO)
12.17
+0.55
(+4.73%)
USD |
NASDAQ |
Sep 04, 15:11
Korro Bio Enterprise Value : 98.06M for Sept. 3, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 03, 2026 | 98.06M |
| September 02, 2026 | 103.20M |
| September 01, 2026 | 107.17M |
| August 31, 2026 | 110.85M |
| August 28, 2026 | 117.03M |
| August 27, 2026 | 122.17M |
| August 26, 2026 | 128.35M |
| August 25, 2026 | 129.08M |
| August 24, 2026 | 119.38M |
| August 21, 2026 | 121.00M |
| August 20, 2026 | 117.76M |
| August 19, 2026 | 132.32M |
| August 18, 2026 | 121.58M |
| August 17, 2026 | 120.41M |
| August 14, 2026 | 122.47M |
| August 13, 2026 | 122.61M |
| August 12, 2026 | 123.50M |
| August 11, 2026 | 123.06M |
| August 10, 2026 | 125.56M |
| August 07, 2026 | 122.03M |
| August 06, 2026 | 105.41M |
| August 05, 2026 | 96.29M |
| August 04, 2026 | 94.09M |
| August 03, 2026 | 85.12M |
| July 31, 2026 | 79.67M |
| Date | Value |
|---|---|
| July 30, 2026 | 80.85M |
| July 29, 2026 | 75.26M |
| July 28, 2026 | 81.59M |
| July 27, 2026 | 84.82M |
| July 24, 2026 | 83.64M |
| July 23, 2026 | 96.73M |
| July 22, 2026 | 99.23M |
| July 21, 2026 | 103.06M |
| July 20, 2026 | 96.29M |
| July 17, 2026 | 107.32M |
| July 16, 2026 | 107.76M |
| July 15, 2026 | 118.79M |
| July 14, 2026 | 122.32M |
| July 13, 2026 | 125.70M |
| July 10, 2026 | 141.29M |
| July 09, 2026 | 137.47M |
| July 08, 2026 | 143.64M |
| July 07, 2026 | 140.26M |
| July 06, 2026 | 133.94M |
| July 02, 2026 | 133.06M |
| July 01, 2026 | 127.91M |
| June 30, 2026 | 121.00M |
| June 29, 2026 | 118.22M |
| June 26, 2026 | 111.08M |
| June 25, 2026 | 103.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.98B |
| Oncolytics Biotech, Inc. | 103.08M |
| Sangamo Therapeutics, Inc. | 60.60M |
| Sarepta Therapeutics, Inc. | 2.686B |
| Anixa Biosciences, Inc. | 88.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.92M |
| Total Expenses (Quarterly) | 18.92M |
| EPS Diluted (Quarterly) | -1.074 |
| Earnings Yield | -82.25% |
| Normalized Earnings Yield | -61.14 |